Immunogenicity and efficacy of a subcutaneously administered, adjuvanted vaccine containing modified S1 spike protein of SARS-CoV-2 variant C.1.2
M. L. Bowe, E. M. Wright, P. Pushko, B. Backstedt, C. Gardner, M. Short-Freeman, S. Kar, D. C. Wright
This paper evaluates a subcutaneously administered vaccine targeting the S1 spike protein of SARS-CoV-2 variant C.1.2, showing robust IgG responses and protection against Omicron BA.1 challenge in hamsters.
bioRxiv · Aug 31, 2023 · PreprintImmunology